NovoCure Limited (NVCR)Healthcare | Medical Devices | Baar, Switzerland | NasdaqGS
12.83 USD
+0.21
(1.664%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 12.93 +0.10 (0.779%) ⇧ (April 17, 2026, 6:18 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 18, 2026, 10:36 p.m. EDT
Extreme long-term caution is warranted due to persistent operational cash burn (-$49M operating CF), negative ROE, and a forward P/E that cannot be calculated (Loss). While recent FDA approvals for Optune Pax and short-term price recovery suggest a potential sentiment reversal, the fundamental health of the company is currently brittle. The long-term investment case is insufficient (Rating 1) until sustainable profitability is demonstrated; the recent surge is likely a short-term promotional trade or momentum play instead of a value reset. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.119323 |
| AutoETS | 0.119325 |
| MSTL | 0.124261 |
| AutoTheta | 0.169516 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 74% |
| H-stat | 1.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.533 |
| Excess Kurtosis | -0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 72.945 |
| Revenue per Share | 5.879 |
| Market Cap | 1,459,982,080 |
| Forward P/E | -11.01 |
| Beta | 0.82 |
| Profit Margins | -20.79% |
| Website | https://www.novocure.com |
As of April 18, 2026, 10:36 p.m. EDT: Options data reveals a distinct asymmetry: speculative call activity is heavily skewed towards high strikes (20-25 range) with massive Open Interest (OI) building at 16, 21, and 25 strikes for May/June expirations. This indicates 'long gamma' positioning or a bullish liquidity play on momentum rather than directional conviction. Conversely, put activity is concentrated at lower strikes (8-10 range) but shows diminishing volume significantly further out, suggesting a lack of borne-out fear for deeper moves. The high OTM positioning percentage calls (>95% for June/Sept/Jan) suggests deep out-of-the-money call buyers are waiting for a catalyst-driven parabolic move, while ATM call positioning remains relatively thin compared to deep OTM. This flow signals a 'momentum contrarian' bias rather than a hedged portfolio position.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.17650837 |
| Address1 | Neuhofstrasse 21 |
| All Time High | 232.76 |
| All Time Low | 5.95 |
| Ask | 16.42 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,153,860 |
| Average Daily Volume3 Month | 1,889,072 |
| Average Volume | 1,889,072 |
| Average Volume10Days | 1,153,860 |
| Beta | 0.819 |
| Bid | 12.8 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 3.027 |
| City | Baar |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 4 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.83 |
| Current Ratio | 2.897 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.15 |
| Day Low | 12.775 |
| Debt To Equity | 72.945 |
| Display Name | NovoCure |
| Earnings Call Timestamp End | 1,777,550,400 |
| Earnings Call Timestamp Start | 1,777,550,400 |
| Earnings Timestamp | 1,777,552,200 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | -135,159,008 |
| Ebitda Margins | -0.20624 |
| Enterprise To Ebitda | -9.327 |
| Enterprise To Revenue | 1.924 |
| Enterprise Value | 1,260,661,120 |
| Eps Current Year | -1.53571 |
| Eps Forward | -1.16571 |
| Eps Trailing Twelve Months | -1.22 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.777 |
| Fifty Day Average Change | 1.0529995 |
| Fifty Day Average Change Percent | 0.08941152 |
| Fifty Two Week Change Percent | -17.650837 |
| Fifty Two Week High | 20.06 |
| Fifty Two Week High Change | -7.2299995 |
| Fifty Two Week High Change Percent | -0.36041874 |
| Fifty Two Week Low | 9.82 |
| Fifty Two Week Low Change | 3.0100002 |
| Fifty Two Week Low Change Percent | 0.30651733 |
| Fifty Two Week Range | 9.82 - 20.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,443,706,200,000 |
| Float Shares | 94,631,420 |
| Forward Eps | -1.16571 |
| Forward P E | -11.006168 |
| Free Cashflow | -37,975,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,605 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.74797 |
| Gross Profits | 490,184,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.094799995 |
| Held Percent Institutions | 0.86772 |
| Implied Shares Outstanding | 113,794,396 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. |
| Long Name | NovoCure Limited |
| Market | us_market |
| Market Cap | 1,459,982,080 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_69172456 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -136,227,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,459,982,100 |
| Number Of Analyst Opinions | 7 |
| Open | 12.99 |
| Operating Cashflow | -49,031,000 |
| Operating Margins | -0.21327 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Post Market Change | 0.10000038 |
| Post Market Change Percent | 0.7794262 |
| Post Market Price | 12.93 |
| Post Market Time | 1,776,464,313 |
| Previous Close | 12.62 |
| Price Eps Current Year | -8.354442 |
| Price Hint | 2 |
| Price To Book | 4.23852 |
| Price To Sales Trailing12 Months | 2.2277796 |
| Profit Margins | -0.20787 |
| Quick Ratio | 2.509 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.71429 |
| Region | US |
| Regular Market Change | 0.21 |
| Regular Market Change Percent | 1.66403 |
| Regular Market Day High | 13.15 |
| Regular Market Day Low | 12.775 |
| Regular Market Day Range | 12.775 - 13.15 |
| Regular Market Open | 12.99 |
| Regular Market Previous Close | 12.62 |
| Regular Market Price | 12.83 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,366,158 |
| Return On Assets | -0.09064 |
| Return On Equity | -0.38886002 |
| Revenue Growth | 0.081 |
| Revenue Per Share | 5.879 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 113,794,396 |
| Shares Percent Shares Out | 0.0796 |
| Shares Short | 9,055,343 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,127,904 |
| Short Name | NovoCure Limited |
| Short Percent Of Float | 0.1245 |
| Short Ratio | 6.78 |
| Source Interval | 15 |
| Symbol | NVCR |
| Target High Price | 49.0 |
| Target Low Price | 13.5 |
| Target Mean Price | 25.07143 |
| Target Median Price | 25.0 |
| Total Cash | 447,673,984 |
| Total Cash Per Share | 3.934 |
| Total Debt | 248,352,992 |
| Total Revenue | 655,353,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.774825 |
| Two Hundred Day Average Change | 0.055174828 |
| Two Hundred Day Average Change Percent | 0.004319028 |
| Type Disp | Equity |
| Volume | 1,366,158 |
| Website | https://www.novocure.com |
| Zip | 6,340 |